Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136873 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
NCT04136873 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 130 participants.
The verdict
NCT04136873, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
Study Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.
Interventions
- DRUG Matching Placebo
- DRUG CVL-231
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136873
The ClinicalTrials.gov registry entry for NCT04136873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT04136873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04136873 about?
NCT04136873 is a clinical study titled "A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia". The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.
What is the current status of trial NCT04136873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2019-10-15. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT04136873?
The interventions under investigation include: Matching Placebo (DRUG), CVL-231 (DRUG).
Who is sponsoring clinical trial NCT04136873?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.